

SELECTIVE LASER TRABECULOPLASTY FOR CHRONIC OPEN ANGLE GLAUCOMA (COAG) CRITERIA BASED ACCESS (CBA) POLICY

| | |
|---|---|
| Version: | 2223.V1c |
| Recommendation by: | NHS Somerset ICB Clinical Commissioning Policy Forum (CCPF) |
| Date Ratified: | April 2023 |
| Name of Originator/Author: | EBI Service |
| Approved by Responsible Committee/Individual: | NHS Somerset ICB Clinical Executive Committee (CEC) |
| Publication/issue date: | May 2023 |
| Review date: | Earliest of either NICE publication or 3 years from issue |
| Target audience: | <p>NHS Somerset ICB:</p> <ul style="list-style-type: none"> • NHS Providers • GP Practices • Contracts Team <p>Medical Directors:</p> <ul style="list-style-type: none"> • Somerset Foundation Trust • Yeovil District Hospital NHS FT • Royal United Hospitals Bath NHS FT |
| Application Form | EBI Generic application form if appropriate to apply |

**SELECTIVE LASER TRABECULOPLASTY FOR CHRONIC OPEN ANGLE
GLAUCOMA (COAG)
CRITERIA BASED ACCESS (CBA) POLICY**

| Section | CONTENTS | Page |
|----------------|--|-------------|
| | Version Control | 1 |
| 1 | General Principles | 2 |
| 2 | Policy Criteria | 3 |
| 3 | Background | 3 |
| 4 | Evidence Based Interventions Application Process | 3-4 |
| 5 | Access To Policy | 4 |
| 6 | References | 4 |

VERSION CONTROL

| | |
|-------------------------|----------------|
| Document Status: | Current policy |
| Version: | 2223.V1c |

DOCUMENT CHANGE HISTORY

| Version | Date | Comments |
|----------------|-------------|--|
| 2021.v1 | July 2022 | Amendment from SCCG to NHS Somerset ICB. New PALS email address |
| 2223.v1a | March 2023 | Wording change on 4.6 |
| 2223.V1b | April 2023 | 3 year review, no clinical changes |

| | |
|---|---------------|
| Equality Impact Assessment (EIA) | |
| Quality Impact Assessment QIA | November 2020 |
| Sponsoring Director: | Bernie Marden |
| Document Reference: | 2223.v1c |

1 GENERAL PRINCIPLES (CBA)

- 1.1 Treatment should only be given in line with these general principles. Where patients are unable to meet these principles, in addition to the specific treatment criteria set out in this policy, funding approval may be sought from the ICB's Evidence Based Interventions Service (EBI) by submission of an EBI application form
- 1.2 Clinicians should assess their patients against the criteria within this policy prior to a referral and/or treatment
- 1.3 Treatment should only be undertaken where the criteria have been met and there is evidence that the treatment requested is effective and the patient has the potential to benefit from the proposed treatment. Where the patient has previously been provided with the treatment with limited or diminishing benefit, it is unlikely that they will qualify for further treatment
- 1.4 Referring patients to secondary / community care without them meeting the criteria or funding approval not secured not only incurs significant costs in out-patient appointments for patients that may not qualify for surgery, but inappropriately raises the patient's expectation of treatment
- 1.5 On limited occasions, the ICB may approve funding for an assessment only in order to confirm or obtain evidence demonstrating whether a patient meets the criteria for funding. In such cases, patients should be made aware that the assessment does not mean that they will be provided with surgery and surgery will only be provided where it can be demonstrated that the patients meet the criteria to access treatment in this policy
- 1.6 Patients should be advised being referred does not confirm that they will receive treatment or surgery for a condition as a consent discussion will need to be undertaken with a clinician prior to treatment
- 1.7 The policy does not apply to patients with suspected malignancy who should continue to be referred under 2 week wait pathway rules for assessment and testing as appropriate
- 1.8 Patients with an elevated BMI of 30 or more may experience more post-surgical complications including post-surgical wound infection so should be encouraged to lose weight further prior to seeking surgery.
<https://www.sciencedirect.com/science/article/pii/S1198743X15007193>
(Thelwall, 2015)
- 1.9 Patients who are smokers should be referred to smoking cessation services in order to reduce the risk of surgery and improve healing

2 POLICY CRITERIA BASED ACCESS (CBA)

- 2.1 Somerset ICB routinely commissions selective laser trabeculoplasty for chronic open angle glaucoma (COAG) as an Out-Patient procedure only
- 2.2 Selective laser trabeculoplasty for COAG should be performed as an out-patient procedure.
- 2.3 People with COAG whose IOP has not been reduced sufficiently following first selective laser trabeculoplasty may be offered a second procedure of selective laser trabeculoplasty
- 2.4 Patients who are not eligible for treatment under this policy, please refer to section 4 EVIDENCE BASED INTERVENTIONS APPLICATION PROCESS on how to apply for funding with evidence of clinical exceptionalality

3 BACKGROUND

- 3.1 NICE guidelines recommend that selective laser trabeculoplasty for chronic open angle glaucoma (COAG) should be one of a number of options for patients
- 3.2 More recent evidence suggests that Selective laser trabeculoplasty should be offered as a first-line treatment for chronic open angle glaucoma
- 3.3 Selective laser trabeculoplasty for chronic open angle glaucoma (COAG) can be safely performed in an outpatient setting

4 EVIDENCE BASED INTERVENTIONS APPLICATION PROCESS

- 4.1 Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or Consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy
- 4.2 Completion of a **Generic EBI Application Form** by a patient's GP or Consultant is required
- 4.3 Applications cannot be considered from patients personally
- 4.4 Only electronically completed EBI applications will be accepted to the EBI Service
- 4.5 It is expected that clinicians will have ensured that the patient, on behalf of who they are forwarding the application for, is appropriately informed about the existing policies prior to an application to the EBI service. This will

reassure the service that the patient has a reasonable expectation of the outcome of the application and its context

4.6 EBI applications are reviewed and considered against clinical exceptionality

For further information on 'clinical exceptionality' please refer to the NHS Somerset ICB website and input into the 'Search this website' box clinical exceptionality. Click on the link to access the full NHS description of clinical exceptionality

Social, Emotional and Environmental factors *i.e., income, housing, environmental pollution, access to services, family, friends, ethnicity, life experiences etc.* CANNOT be considered with an application

4.7 Where appropriate photographic supporting evidence can be forwarded with the application form

4.8 An application put forward for consideration must demonstrated some unusual or unique clinical factor about the patient that suggests they are exceptional as defined below:

- Significantly different to the general population of patients with the condition in question
- Likely to gain significantly more benefit from the intervention than might be expected from the average patient with the condition

5 ACCESS TO POLICY

5.1 If you would like further copies of this policy or need it in another format, such as Braille or another language, please contact the Patient Advice and Liaison Service on Telephone number: 08000 851067

5.2 **Or write to us:** NHS Somerset ICB, Freepost RRKL-XKSC-ACSG, Yeovil, Somerset, BA22 8HR or **Email** us: somicb.pals@nhs.net

6 REFERENCES

The following sources have been considered when drafting this policy:

6.1 NICE guidance:

<https://www.nice.org.uk/guidance/ng81/resources/glaucoma-diagnosis-and-management-pdf-1837689655237>

6.2 <https://www.nice.org.uk/guidance/ng81/resources/2019-exceptional-surveillance-of-glaucoma-diagnosis-and-management-nice-guideline-ng81-6901877773/chapter/Surveillance-decision?tab=evidence>

6.2 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)32213-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32213-X/fulltext)

